Why the study?
Do rivaroxaban or dabigatran increase bleeding risks compared to apixaban in patients with non-valvular atrial fibrillation?
Do rivaroxaban or dabigatran increase bleeding risks compared to apixaban in patients with non-valvular atrial fibrillation?
Real-world data suggests rivaroxaban is associated with higher bleeding risks than apixaban in NVAF patients, while dabigatran and apixaban have comparable bleeding safety profiles.
No takes yet. Share an insight, caveat, or question.
Rivaroxaban may carry higher bleeding risk than apixaban in NVAF; leaves open confirmation beyond observational cohorts.
Tepper et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: